PLX

Business Context and Reporting Period

Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: Protalix is a biopharmaceutical company developing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The lead product candidate is taliglucerase alfa for the treatment of Gaucher disease. In November 2009, the company entered an exclusive license and supply agreement with Pfizer Inc. for worldwide rights (excluding Israel) to taliglucerase alfa.

Key Financial Metrics

Liquidity and Debt: As of June 30, 2010, the company held $54.96 million in cash and cash equivalents. Total liabilities were $75.78 million, primarily consisting of deferred revenues ($62.33 million total, split between current and long-term) related to the Pfizer agreement. The company reported a capital deficiency of $1.55 million.

Material Changes vs. Prior Period

• Revenue Growth: Revenues for the six months ended June 30, 2010, increased to $2.3 million from $1.1 million in the prior year period. This revenue is derived from the pro rata amortization of the $60 million upfront payment and $5 million milestone payment received from Pfizer.
• Increased R&D Spend: Research and development expenses rose 72% to $19.4 million (from $11.3 million). This increase was driven by higher salaries, material costs, consulting fees, and costs associated with the Pfizer agreement, reflecting expanded clinical trial sites and new projects.
• Widening Net Loss: Net loss increased to $18.0 million from $10.6 million due to the significant rise in operating expenses outpacing revenue recognition.
• Cash Position: Cash and cash equivalents decreased by $26.3 million during the six-month period, primarily due to operating losses and capital expenditures for property and equipment ($5.5 million).

Guidance, Outlook, and Risks

Regulatory Status: The FDA accepted the New Drug Application (NDA) for taliglucerase alfa in July 2010 and assigned a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011. The company completed a Phase I clinical trial for PRX-105 (biodefense candidate) in June 2010.

Outlook: Management expects to continue generating losses over the next several years due to ongoing R&D activities and commercialization costs for the launch of taliglucerase alfa in Israel. The company believes current cash resources are sufficient for the foreseeable future but may require additional financing for a new manufacturing facility or if assumptions regarding capital needs change.

Risks and Contingencies:

• Regulatory Approval: No assurance exists that the FDA or other authorities will approve taliglucerase alfa or other candidates.
• Financing: The company may need to raise additional funds through equity or debt offerings, which could result in dilution or restrictive covenants.
• Operational Risks: Risks include delays in clinical trials, patient enrollment issues, competition, and potential disruption from geopolitical events in Israel.

Investor Verification Checklist

• FDA PDUFA Date: Verify the February 25, 2011, action date for the taliglucerase alfa NDA and any subsequent communications from the FDA.
• Cash Burn Rate: Monitor the rate of cash consumption ($20.8 million used in operations over six months) against the $55 million cash balance to assess runway.
• Pfizer Agreement Milestones: Track the achievement of the $50 million in potential milestone payments and the 40% royalty structure on net profits.
• Manufacturing Capacity: Confirm plans and capital requirements for the potential new manufacturing facility mentioned in the liquidity section.
• Deferred Revenue Recognition: Review the amortization schedule of the $65 million Pfizer payments to understand future revenue recognition patterns.